Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ketamine Analog
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MIRA Shows Positive Ketamir-2 Data in Diabetic Neuropathy Animal Study
Details : Ketamir-2 is a non-opioid alternative, an oral ketamine analog, currently is being validated in animal model for diabetic neuropathy.
Product Name : Ketamir-2
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 16, 2025
Lead Product(s) : Ketamine Analog
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MIRA Starts Phase 1 Trial for Ketamir-2 in Neuropathic Pain
Details : Ketamir-2 (ketamine analog), a novel oral, NMDA receptor inhibitor which is being evaluated for the treatment of patients suffering from neuropathic pain.
Product Name : Ketamir-2
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 04, 2025
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MIRA Pharmaceuticals Submits IND for Ketamir-2, a Milestone in Company’s Development
Details : Ketamir-2 (ketamine analog), a novel oral, NMDA receptor inhibitor which is being evaluated for the treatment of patients suffering from neuropathic pain.
Product Name : Ketamir-2
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 19, 2024
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MIRA Pharmaceuticals Validates Ketamir-2 Safety for IND Submission
Details : Ketamir-2 (ketamine analog), a novel oral, NMDA receptor inhibitor which is being evaluated for the treatment of patients suffering from neuropathic pain.
Product Name : Ketamir-2
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 10, 2024
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site
Details : Ketamir-2 (ketamine analog), a novel oral, NMDA receptor inhibitor which is being evaluated for the treatment of patients suffering from neuropathic pain.
Product Name : Ketamir-2
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 20, 2024
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MIRA Pharmaceuticals Submits Pre-IND Meeting Request for Ketamir-2 for Neuropathic Pain
Details : Ketamir-2 (ketamine analog), a novel oral, NMDA receptor inhibitor which is being evaluated for the treatmen of patients suffering from neuropathic pain.
Product Name : Ketamir-2
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 09, 2024
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MIRA Pharma's Ketamir-2 Shows 60% Greater Efficacy Than Gabapentin
Details : Ketamir-2 (ketamine analog), a novel oral, NMDA receptor inhibitor which is being evaluated for the treatment of patients suffering from neuropathic pain.
Product Name : Ketamir-2
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 28, 2024
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MIRA’s Ketamir-2 Outperforms Gabapentin & Pregabalin in Neuropathic Pain Study
Details : Ketamir-2 (ketamine analog), a novel oral, NMDA receptor inhibitor which is being evaluated for the treatment of patients suffering from neuropathic pain.
Product Name : Ketamir-2
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 21, 2024
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MIRA Advances Ketamir-2 Development Following Phase 1 Design Completion for Pain
Details : Ketamir-2 (ketamine analog), a novel oral, NMDA receptor inhibitor which is being evaluated for the treatmen of patients suffering from neuropathic pain.
Product Name : Ketamir-2
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 18, 2024
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MIRA Pharmaceuticals Achieves 100% Neuropathic Pain Reversal with Oral Ketamir-2
Details : Ketamir-2 (ketamine analog), a novel oral, NMDA receptor inhibitor which is being evaluated for the treatmen of patients suffering from neuropathic pain.
Product Name : Ketamir-2
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 26, 2024
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable